Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity (NASDAQ:VIR)
· seekingalpha.com
Vir Biotechnology has a cash runway into 2028 and pivotal 2026 catalysts for its lead hepatitis drugs. Learn why VIR stock is a buy.
Vir Biotechnology, Inc. ( VIR ) had been generating revenue for a while during COVID-19, but after their monoclonal antibody called sotrovimab stopped working d...